We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
+38.46%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
+$363M
(+40%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
18.46%
Top 10 Holdings %
Top 10 Hldgs %
58.32%
Holding
38
New
9
Increased
5
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$146M |
| 2 |
ATXS
Astria Therapeutics
ATXS
|
+$65.7M |
| 3 |
Keros Therapeutics
KROS
|
+$52.1M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$39.3M |
| 5 |
Ocular Therapeutix
OCUL
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$58.4M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$54.1M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$45.3M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$29.8M |
| 5 |
Structure Therapeutics
GPCR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
| $13.8M | 1.09% |
1,163,356
-2,232,139
| -66% | -$29.8M |
|
27
C4 Therapeutics
CCCC
$389M
| $10.4M | 0.82% |
1,276,574
| – | – |
|
28
Entrada Therapeutics
TRDA
$227M
| $8.29M | 0.66% |
584,955
| – | – |
|
29
AN2 Therapeutics
ANTX
$174M
| $5.05M | 0.4% |
1,555,118
-1,123,091
| -42% | -$12.2M |
|
30
Kodiak Sciences
KOD
$2.5B
| $4.73M | 0.37% |
899,999
+632,058
| +236% | +$3.1M |
|
|
VTYX
31
DELISTED
Ventyx Biosciences
VTYX
| $4.49M | 0.35% |
815,724
| – | – |
|
32
Nektar Therapeutics
NKTR
$2.37B
| $3.74M | 0.3% |
+266,667
| New | +$2.79M |
|
33
Cabaletta Bio
CABA
$439M
| $1.48M | 0.12% |
86,795
-400,000
| -82% | -$8.59M |
|
34
Nurix Therapeutics
NRIX
$2.42B
| – | – |
-717,654
| Closed | -$7.41M |
|
35
Taysha Gene Therapies
TSHA
$1.59B
| – | – |
-2,912,861
| Closed | -$5.16M |
|
|
RYZB
36
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – |
-869,908
| Closed | -$54.1M |
|
|
GRCL
37
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| – | – |
-4,514,786
| Closed | -$45.3M |
|
|
ICVX
38
DELISTED
Icosavax, Inc. Common Stock
ICVX
| – | – |
-3,703,704
| Closed | -$58.4M |
|
Similar funds
DILIC
KCM
ACM
BCP
ACA
MSC
TH
PMG
TCG Crossover Management's Q1 2024 Portfolio in Review
As of Q1 2024, TCG Crossover Management held 38 positions worth $1.26B, up 40% from $902M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
TCG Crossover Management deployed $234M of net new capital in Q1 2024, opening 9 new positions and adding to 5 existing holdings. Its largest new stake was CG Oncology: 3,570,206 shares worth $157M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was KalVista Pharmaceuticals, an estimated $29.8M trimmed.
- TCG Crossover Management's largest Q1 2024 buy was CG Oncology: 3,570,206 shares worth $157M.
- TCG Crossover Management added most to Silence Therapeutics in Q1 2024, an estimated $25.9M increase.
- TCG Crossover Management's biggest Q1 2024 reduction was KalVista Pharmaceuticals, cutting an estimated $29.8M.
- TCG Crossover Management fully exited Icosavax, Inc. Common Stock in Q1 2024, selling an estimated $58.4M.
- TCG Crossover Management's ten largest holdings make up 58% of its $1.26B portfolio in Q1 2024.
- TCG Crossover Management opened 9 new positions and closed 5 in Q1 2024.
- TCG Crossover Management's portfolio value rose 40% quarter-over-quarter to $1.26B.
Based on TCG Crossover Management's 13F filing for Q1 2024, filed 15 May 2024.